NFX — Nuformix Income Statement
0.000.00%
Last trade - 00:00
- £1.56m
- £1.35m
- 18
- 52
- 10
- 15
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 18 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.61 | 0.535 | 0.196 | 0.05 | 0 |
Cost of Revenue | |||||
Gross Profit | 0.072 | 0.201 | 0.133 | 0.048 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2.42 | 1.45 | 1.57 | 1.32 | 0.928 |
Operating Profit | -1.81 | -0.914 | -1.37 | -1.27 | -0.928 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -1.84 | -0.93 | -1.38 | -1.27 | -0.928 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.66 | -0.756 | -1.25 | -1.11 | -0.859 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.66 | -0.756 | -1.25 | -1.11 | -0.859 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.66 | -0.756 | -1.25 | -1.11 | -0.859 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.002 | -0.002 | -0.002 | -0.002 | -0.001 |
Dividends per Share |